A new early-stage clinical study reports that targeting tumor metabolism and immune recognition may offer a workable strategy for patients with microsatellite-stable colorectal cancer, a subtype that often resists immunotherapy. In the phase 1/2 trial, researchers combined the PI3K inhibitor copanlisib with nivolumab, an immune checkpoint blocker, and evaluated whether the drug pairing could overcome resistance mechanisms that limit benefit from checkpoint therapy alone.
Copanlisib was designed to interfere with PI3K signaling, a pathway frequently implicated in cancer growth and immune evasion. By dampening this signaling, the therapy aims to reshape the tumor microenvironment—potentially improving antigen presentation and enabling immune cells to infiltrate and sustain antitumor activity.
Nivolumab, which targets PD-1, releases an immunologic brake on T cells. However, in microsatellite-stable tumors, the lack of strong mismatch-repair–driven immunogenic signals has historically resulted in low response rates. The trial therefore tested whether metabolic and signaling suppression by copanlisib could “prime” the immune system enough for nivolumab to work more effectively.
The investigators enrolled participants with microsatellite-stable colorectal cancer and used a dose-escalation and expansion approach typical of phase 1/2 studies. Safety, tolerability, and preliminary efficacy were tracked alongside immune- and tumor-related biomarkers, seeking evidence that the combination produced measurable biological effects.
Across the study framework, attention focused on whether the regimen could generate durable clinical responses without unacceptable toxicity. The trial’s early findings suggest that the combination can be administered with a manageable safety profile, while offering signals of antitumor activity.
Crucially, the researchers also assessed mechanistic indicators linked to immune engagement. These included changes in immune cell activity within the tumor milieu and evidence that PI3K pathway inhibition could influence how tumors interact with infiltrating lymphocytes.
While definitive effectiveness estimates will require larger randomized trials, the work highlights a rational combination route: pairing pathway inhibition with checkpoint blockade in cancers where immunotherapy alone has been less fruitful.
The study also underscores the broader idea that “cold” tumors—those with limited baseline immune visibility—may be made more vulnerable by altering intracellular signaling networks that support immune escape.
Overall, this Viral science news update points to copanlisib plus nivolumab as a promising direction for microsatellite-stable colorectal cancer, offering a template for future trials that integrate targeted signaling suppression with immunotherapy.
Subject of Research: Copanlisib plus nivolumab in microsatellite-stable colorectal cancer
Article Title: Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial
Article References: Christenson, E.S., Wala, J.A., Parkinson, R. et al. Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial. Nat Commun 17, 7114 (2026). https://doi.org/10.1038/s41467-026-72985-6
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41467-026-72985-6
Tags: combination immunotherapy trialsimmune biomarkers in cancer treatmentimmune response enhancement in colorectal cancerimmune system priming strategieslow response in microsatellite-stable tumorsmicrosatellite stable colorectal cancernivolumab immune checkpoint blockadeovercoming immunotherapy resistancephase 1/2 cancer clinical studyPI3K inhibitor copanlisibtumor metabolism targetingtumor microenvironment modulation
